

# Global Proteomic Analysis of Human Liver Microsomes: Rapid Characterization and Quantification of Hepatic Drug-Metabolizing Enzymes<sup>§</sup>

Brahim Achour, Hajar Al Feteisi, Francesco Lanucara, Amin Rostami-Hodjegan, and Jill Barber

*Centre for Applied Pharmacokinetic Research, Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Manchester (B.A., H.A.F., A.R.-H., J.B.), Waters Corporation, Wilmslow, Cheshire East (F.L.), and Simcyp Limited (a Certara Company), Blades Enterprise Centre, Sheffield (A.R.-H.), United Kingdom*

Received December 19, 2016; accepted March 30, 2017

## ABSTRACT

Many genetic and environmental factors lead to interindividual variations in the metabolism and transport of drugs, profoundly affecting efficacy and toxicity. Precision dosing, that is, targeting drug dose to a well characterized subpopulation, is dependent on quantitative models of the profiles of drug-metabolizing enzymes (DMEs) and transporters within that subpopulation, informed by quantitative proteomics. We report the first use of ion mobility–mass spectrometry for this purpose, allowing rapid, robust, label-free quantification of human liver microsomal (HLM) proteins from distinct individuals. Approximately 1000 proteins were identified and quantified in four samples, including an average of 70 DMEs. Technical and biological variabilities were distinguishable, with technical variability accounting for about 10% of total variability. The biological variation between patients was clearly identified, with samples showing a range of expression profiles for cytochrome

P450 and uridine 5'-diphosphoglucuronosyltransferase enzymes. Our results showed excellent agreement with previous data from targeted methods. The label-free method, however, allowed a fuller characterization of the *in vitro* system, showing, for the first time, that HLMs are significantly heterogeneous. Further, the traditional units of measurement of DMEs (pmol mg<sup>-1</sup> HLM protein) are shown to introduce error arising from variability in unrelated, highly abundant proteins. Simulations of this variability suggest that up to 1.7-fold variation in apparent CYP3A4 abundance is artifactual, as are background positive correlations of up to 0.2 (Spearman correlation coefficient) between the abundances of DMEs. We suggest that protein concentrations used in pharmacokinetic predictions and scaling to *in vivo* clinical situations (physiologically based pharmacokinetics and *in vitro-in vivo* extrapolation) should be referenced instead to tissue mass.

## Introduction

Designing patient-specific dosage regimens within the framework of precision medicine has recently been emphasized as a key future direction in biomedical and pharmaceutical research, with physiologically based pharmacokinetics (PBPK) and *in vitro-in vivo* extrapolation expected to play an important role in this application (Jamei, 2016). In pharmacogenomics, one of the pillars of personalized medicine, a survey of 517 submissions assessed by the European Medicines Agency between 1995 and 2014 showed that approximately 15% of approved medications have on-label pharmacogenomic information that directly affects therapy, indicating the recent move into tailoring drug use for specific patient subpopulations (Ehmann et al., 2015). Within this framework of targeted therapy evaluation, *in vitro-in vivo* extrapolation-PBPK is expected to shift its focus to subpopulations with specific therapeutic needs, with increasing demand to populate these new models

with expression and functional data of proteins involved in absorption, distribution, metabolism, and excretion (ADME) (Turner et al., 2015; Jamei, 2016). This expectation is supported by the substantial number of novel drug submissions (136 between 2008 and 2014) to the Food and Drug Administration for approval where PBPK has beneficially informed drug development, especially in the areas of drug-drug interactions and pediatrics (Huang et al., 2013; Jamei, 2016). Comprehensive and detailed information about the abundance and activity of ADME proteins, which play a central role in drug metabolism and disposition, is therefore required and crucially needs to be generated with clear inter-relations with genetic, demographic, environmental, and clinical information (Schadt and Björkegren, 2012; Turner et al., 2015).

Proteomics is expected to play a more prominent role in the qualitative and quantitative characterization of proteins involved in disease development and progression and modulating drug therapy, with applications ranging from biomarker discovery and disease monitoring to design of dosage regimens (Masys et al., 2012; Auffray et al., 2016). Biomolecular data acquisition and analysis should be guided by the intended clinical application, with particular emphasis on disease prevention and therapy based on interindividual variability in genetic, lifestyle, and environmental factors (McGrath and Ghersi, 2016).

This work was supported by the Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester.

<https://doi.org/10.1124/dmd.116.074732>

<sup>§</sup>This article has supplemental material available at [dmd.aspetjournals.org](http://dmd.aspetjournals.org).

**ABBREVIATIONS:** ADME, absorption, distribution, metabolism and excretion; DME, drug-metabolizing enzyme; HLM, human liver microsome; HPLC, high-performance liquid chromatography; IMS, ion-mobility spectrometry; LC, liquid chromatography; MALDI-TOF, matrix-assisted laser desorption ionization/time-of-flight; MS, mass spectrometry; MS<sup>E</sup>, data-independent acquisition mass spectrometry; MS/MS, tandem mass spectrometry; P450, cytochrome P450; PBPK, physiologically based pharmacokinetics; QconCAT, quantification concatemer; UGT, uridine 5'-diphosphoglucuronosyltransferase.

With recent advances in tandem mass spectrometry (MS/MS), many laboratories have started to contribute to the wealth of literature about ADME protein abundance (Ohtsuki et al., 2012; Prasad et al., 2014; Achour et al., 2014a; Harwood et al., 2015; Vildhede et al., 2015; Fallon et al., 2016). Protein abundance values from these experiments are used in several drug pharmacokinetic prediction exercises, including scaling parameters from in vitro models to in vivo clinical situations using computational PBPK models (Rostami-Hodjegan, 2012; Knights et al., 2016); however, cross-laboratory and interstudy heterogeneity highlighted recently (Achour et al., 2014b; Badée et al., 2015) have led to ongoing efforts to investigate variability originating from using different methodological workflows, taking into consideration their advantages and limitations in relation to their intended applications (Harwood et al., 2016; Al Feteisi et al., 2015).

There is little consistency in proteomic protocols used for protein quantification in a wide variety of samples, including heterogeneous membrane fractions: crude total membrane, plasma membrane and microsomal fractions (Schaefer et al., 2012; Fallon et al., 2013; Gröer et al., 2013; Russell et al., 2013), and whole tissue lysates (Wiśniewski et al., 2014; Weiß et al., 2015; Wiśniewski et al., 2016a). The effects of different methodological processes on determining protein abundance were previously investigated with different levels of evidence, sometimes of conflicting nature; however, the general idea emphasized by these studies is that differences in sample preparation and in proteomic methods can contribute to considerable overall variability in endpoint measurements (Balogh et al., 2013; Qiu et al., 2013; Chiva et al., 2014; Harwood et al., 2016), which makes assessment of true biologic interindividual variability a difficult challenge. Different mass spectrometry (MS) platforms can also have an effect on the quality and robustness of analysis, with promising improvements in instrumentation making proteomic analysis more reliable. Particularly, liquid chromatography (LC) in conjunction with ion mobility spectrometry (IMS) and MS/MS, is a relatively new approach that allows robust global analysis of entire proteomes and has recently been applied to proteomic analysis of HeLa cell lines (Distler et al., 2014) and breast tumor xenografts (Burnum-Johnson et al., 2016).

This report describes a proof-of-concept study that aims to apply a LC-IMS-MS/MS proteomic approach to the analysis of the human liver microsomal (HLM) proteome, with specific focus on quantification of the expression of drug-metabolizing enzymes (DMEs). Implications of this quantitative assessment for enzyme abundance measurements and expression correlations are subsequently considered.

## Materials and Methods

**Materials and Chemicals.** All reagents were obtained from Sigma-Aldrich (Poole, Dorset, UK) unless otherwise indicated. Lysyl endopeptidase was purchased from Wako (Osaka, Japan), and recombinant proteomic-grade trypsin was supplied by Roche Applied Sciences (Mannheim, Germany). Label-free protein standards at 95% purity (bovine serum albumin, bovine cytochrome *c*, equine myoglobin) were purchased from Sigma-Aldrich. Solvents were of high-performance liquid chromatography (HPLC) grade.

**HLM Samples.** We used four individual HLMs (nominally labeled HLM01, HLM02, HLM03, and HLM04) provided by Pfizer (Groton, CT), along with demographic, medication, and genotype details of donors. Table 1 shows demographic and clinical information on the donors; suppliers of these samples were Vitron (Tucson, AZ) and BD Gentest (San Jose, CA). The same microsomal samples were used in the quantitative experiments using the label-free approach (the present study) and the quantification concatenator (QconCAT) targeted approach (Achour et al., 2014a), which was used to analyze samples HLM01, HLM02, and HLM04. Microsomal fractions were prepared from liver tissue by the two suppliers, both using fractionation methods based on differential centrifugation of hepatic tissue homogenates. Low-speed centrifugation (10,000 *g*) was used to separate the S9 fraction (supernatant), followed by an ultracentrifugation step (100,000 *g*) to isolate the microsomal fraction (pellet). Ethics were covered by the suppliers.

**Methodological Workflows.** Supplemental Fig. 1 shows a summary of the label-free global proteomic workflow followed in this study. The targeted QconCAT method is described elsewhere (Achour et al., 2014a). Differences between the methodological steps in these approaches are shown in Supplemental Table 1.

**Proteolytic Digestion of HLM Samples and Estimation of Protein Loss.** Protein content in microsomal samples was determined using a colorimetric protein assay (Bradford, 1976). Proteolytic digestion and gravimetric estimation of peptide loss were carried out in triplicate using methods previously reported by Harwood et al. (2015) with slight modifications. Briefly, HLM samples (50  $\mu$ g total protein mass) were suspended in ammonium bicarbonate buffer (25 mM, pH 8.0) and combined with a standard mixture of unlabeled bovine serum albumin, equine myoglobin, and bovine cytochrome *c* (6  $\mu$ l, at 0.1, 0.02, and 0.01 mg ml<sup>-1</sup>, respectively) to a final volume of 50  $\mu$ l. The rationale for using nonhuman standard proteins is that species-specific peptides can be found in reference proteins that should not be found in the target human proteome to allow quantification without interference from homology in protein sequences. Mixtures were then denatured with sodium deoxycholate (acid-labile detergent) at a final concentration of 10% (w/v) for 10 minutes at room temperature. Disulfide bonds were reduced (dithiothreitol, 60 mM final concentration) at 56°C for 20 minutes and subsequently alkylated (iodoacetamide, 15 mM final concentration) in the dark at room temperature for 30 minutes.

Sequential enzyme proteolysis was used to increase the scope and depth of analysis and reduce the number of missed cleavages (Wiśniewski and Mann, 2012; Achour and Barber, 2013; Al-Majdoub et al., 2014). Samples were diluted 1:10 with ammonium bicarbonate (25 mM) and 1  $\mu$ l of lysyl endopeptidase (1  $\mu$ g  $\mu$ l<sup>-1</sup>) was added, followed by incubation at 30°C for 4 hours. Trypsin (2.5  $\mu$ l, 1  $\mu$ g  $\mu$ l<sup>-1</sup>) was then added, followed by incubation at 37°C for 18 hours. After removal of detergent by acidification with trifluoroacetic acid (~pH 3.0) and centrifugation, the supernatant containing the peptides was retained and evaporated by vacuum centrifugation. Peptide loss was estimated gravimetrically as described previously (Harwood et al., 2015). Supplemental Fig. 2 shows the measured protein concentration in the HLM samples and the mass of recovered peptides after sample preparation.

**Matrix-Assisted Laser Desorption Ionization/Time-of-Flight MS Analysis.** To confirm the quality of sample protein digests before LC-IMS-MS/MS analysis, digested samples were analyzed using matrix-assisted laser desorption ionization/time-of-flight (MALDI-TOF) MS performed on an Ultraflex II instrument (Bruker, Bremen, Germany); 20 mg ml<sup>-1</sup> MALDI matrix was prepared by dissolving  $\alpha$ -cyano-4-hydroxycinnamic acid (Fluka, Buchs, Switzerland) in 0.1% trifluoroacetic acid in 50% acetonitrile in HPLC water. Samples (0.5  $\mu$ l) were applied onto a MALDI target plate in triplicate. Once dry, matrix solution (0.5  $\mu$ l) was added, and then the

TABLE 1  
Demographic and clinical details of the individual liver donors of samples used in this study

The final column shows the suppliers of samples. HLM samples were prepared by the suppliers using differential centrifugation of hepatic tissue homogenates.

Patient Sample	Age (yr)	Ethnicity	Gender	Cause of Death	Smoking	Alcohol Use	Medical History	Medication	Supplier
HLM01	31	C	F	Motor vehicle accident	Yes	No	None	None	BD Gentest
HLM02	62	C	F	Head trauma	No	No	Hypertension	Hypertension medications	BD Gentest
HLM03	41	H	F	CVA	No	Occasional	Hypertension, mild stroke	Atenolol, dobutamine, morphine, Nuprin	BD Gentest
HLM04	50	C	M	CVA	No	No	Healthy	None	Vitron

C, Caucasian; CVA, cerebrovascular aneurysm; H, Hispanic; F, Female; M, male.

mixture was allowed to dry. Spectra were acquired in two  $m/z$  ranges (700–2500 and 700–5000) to check for miscleaved peptides. Laser frequency of 100 Hz and intensity of 30%–35% were used. Spectra of 2000 laser shots were acquired per spot. Analyses of MALD-TOF MS data were performed using FlexAnalysis version 2.2 (Bruker). Quality of spectra was checked for peptide peak intensities and  $m/z$  range before proceeding to LC-MS experiments.

**LC-IMS-MS/MS.** Prepared HLM peptide samples were diluted 1:10, of which 2  $\mu$ l was analyzed from each diluted sample. The mean HLM peptide mass analyzed in each run was  $44.53 \pm 5.19$  ng (range, 39.59–49.66 ng). Analysis was carried out on a nanoACQUITY ultra-high-performance LC system (Waters, Manchester, UK) connected to a SYNAPT G2-Si mass spectrometer (Waters). For reversed-phase LC, peptides were injected onto a Symmetry C<sub>18</sub> trap column (5  $\mu$ m, 180  $\mu$ m  $\times$  20 mm) and then eluted onto a HSS T3 analytical column (1.8  $\mu$ m, 75  $\mu$ m  $\times$  250 mm), maintained at 35°C. The LC program consisted of a gradient of 3%–60% acetonitrile in HPLC water (acidified with 0.1% v/v formic acid) over 40 minutes with a flow rate of 300 nl min<sup>-1</sup>, followed by a ramp to 95% acetonitrile for 5 minutes, and then a return to the initial conditions over 10 minutes.

MS was performed based on data-independent acquisition using high-definition MS<sup>E</sup> methods (Distler et al., 2014). The following acquisition parameters were used on the SYNAPT G2-Si: HDMS<sup>E</sup>, positive electrospray mode, V optics, scan time of 0.5 seconds, cone voltage of 25 V,  $m/z$  range 50–2000, and lock mass [Glu<sup>1</sup>]-fibrinopeptide B [M + 2H]<sup>2+</sup> 785.8426  $m/z$ . Collision energy was ramped based on the mobility of ions for optimal collision-induced dissociation (CID). T-wave ion mobility (IMS) parameters were as follows: IMS T-wave height 40 V, wave velocity 400–800 m second<sup>-1</sup>, helium cell gas flow 180 ml min<sup>-1</sup>, IMS gas flow 90 ml min<sup>-1</sup>, mobility trapping release time 450 microseconds, and trap height 15 V.

**Analysis of MS<sup>E</sup> Data and Database Searching.** Analysis and searching of the LC-IMS-MS/MS data were performed using the ProteinLynx Global Server version 3.0.2 and Identity<sup>E</sup> (Waters) search engine, whereby the precursor ions were aligned based on retention time and drift time. Once the fragment and parent data were matched, identification was carried out by searching against a customized database containing protein sequences from human UniProt database (154,434 sequences; January 2015) and the three reference proteins. Quantification was performed using the summed intensity of the top three peptide ions based on the acquired label-free data for the proteins of interest and the standard proteins. The following quantification equation (eq. 1) was applied:

$$[Protein] = [Standard] \cdot \left( \frac{\sum_{i=1}^3 IonIntensity_{protein}}{\sum_{i=1}^3 IonIntensity_{standard}} \right) \quad (1)$$

where [Protein] represents the abundance of a target protein, [Standard] represents the abundance of the spiked standard in the sample (expressed in units of pmol mg<sup>-1</sup> HLM protein), and the fraction refers to the ratio of the sum of the intensities of the three highest ion peaks for the target protein relative to the standard, as described previously (Silva et al., 2006). The integrated peak intensities of eluted peptides were used for quantification, and calculations of the summed peak intensities were performed by ProteinLynx Global Serve software.

This “top 3 CID” approach is an empirical label-free quantification method, previously shown to produce accurate quantification of mixtures of protein standards (Silva et al., 2006) and to correlate with data from targeted proteomic analysis (Carroll et al., 2011). Other label-free approaches include the total protein approach, based on all quantifiable unique and ‘razor’ peptides from each target protein, an approach that was also previously applied to quantifying hepatic ADME proteins (Vilhedehede et al., 2015).

Any quantitative data below the limit of quantification were not considered reliable. The limit of quantification was nominally set using two criteria: the peptides had to be reliably identified in all three technical replicates, and the replicate intensities of the peptides had to be within 20% CV of each other (i.e., consistent identification and reproducible quantification). Further appraisal of the protein standards used in this analysis is included in the Supplemental Material.

**Protein Data Annotation for Function and Subcellular Localization.** Proteins were classified based on their subcellular localization and function according to Gene Ontology Project annotations (<http://geneontology.org/>) and database searching (<http://www.uniprot.org/>).

**Meta-analysis of Hepatic Microsomal Protein Abundance.** To assess the effects of variability in the most abundant 10 proteins on the endpoint abundance of cytochrome P450 (P450) enzymes and their expression correlations, we used a

Matlab model. To inform the model with abundance values for these proteins, Medline/Pubmed (<http://www.nlm.nih.gov/bsd/pmresources.html>) and Web of Knowledge (<http://wok.mimas.ac.uk/>) electronic databases (between the years 1980 and 2016) were searched for relevant literature on the protein expression of abundant liver microsomal proteins (see Table 2 for a list of these proteins) using suitable keywords including the protein name/gene name (e.g., carboxylesterase 1/CES1), human liver/human hepatic, protein quantification/expression/abundance, and microsomes/HLMs. Searches were combined, and articles were inspected for relevant data. Inclusion criteria were studies that quantified primarily microsomal proteins/enzymes identified in the present analysis in adult human livers in units of, or convertible to, pmol mg<sup>-1</sup> HLM protein. This analysis was used to select the ranges of the 10 most highly expressed proteins in HLM samples. For the two target enzyme families [cytochrome P450 and uridine 5'-diphosphoglucuronosyltransferase (UGT) enzymes], previously published meta-analyses on cytochrome P450 (Achour et al., 2014b) and UGT abundance data (Achour et al., 2014c) were used, assuming ranges and mean abundances have not changed significantly in the last 2 years.

**Statistical Data Analysis and Modeling.** Microsoft Excel 2010 and GraphPad Prism version 7.01 (GraphPad Software, San Diego, CA) were used for data analysis and generating graphs. Venn diagrams were generated using Venny version 2.1 (BioinfoGP, <http://bioinfo.gp.cnb.csic.es/tools/venny/>). To obtain data from graphs in publications in the meta-analysis step, we used GetData Graph Digitizer version 2.26 (<http://www.getdata-graph-digitizer.com/>). The heat map was generated using QCanvas version 1.2.1 (Kim et al., 2012). Matlab R2015a (MathWorks Inc., Natick, MA) was used for modeling effects of variability of the most abundant HLM proteins on abundance and correlation of P450 enzymes. Simulation was repeated 10 times for  $n = 2000$  livers in each simulation step.

## Results

In this study, we set out to obtain a snapshot of the drug-metabolizing subproteome of four human livers, with a focus on rapid and robust sample preparation and measurement. The methods used in this work consisted of in-solution preparation of samples, followed by nanoLC-Q-IMS-TOF MS/MS (i.e., nanoflow-LC, MS, and ion mobility both at the peptide level, then MS at the fragment level (Supplemental Fig. 1). The main aim was to identify and comprehensively quantify a complex hepatic subproteome in a relatively short time (<1 hour), with particular focus on DMEs.

**Assessment of Protein Abundance Measurements.** The starting total protein mass for all samples was 50  $\mu$ g, of which  $35.50 \pm 2.22$   $\mu$ g (range 33.78–38.74  $\mu$ g) was recovered (Supplemental Fig. 2), indicating an overall recovery of 71% as estimated gravimetrically (Harwood et al., 2015). The number of identified proteins was 901–1018 proteins, of which 706–816 were quantifiable (Fig. 1A), with abundances above the lower limit of quantification, estimated at  $\sim 0.03$  fmol peptide (translating to protein abundance of  $\sim 0.6$  pmol mg<sup>-1</sup>).

To assess the reproducibility and precision of the methods, overlap of the number of quantified proteins between samples was estimated, and the coefficients of variation related to technical replicates were calculated. In addition, the relative error of measurements was estimated for drug-metabolizing P450 and UGT enzymes, which were quantified previously in three of the four HLM samples using QconCAT methods (Achour et al., 2014a) (Supplemental Table 3) to allow cross-method comparison. The number of quantified DMEs ranged from 63 to 76, containing 10–14 drug-metabolizing P450 enzymes and 9–11 drug-metabolizing UGT enzymes (Fig. 1B). Overlap of the quantified enzymes, including P450 and UGT enzymes, between the four samples is shown in Supplemental Fig. 4. Figure 1C shows significant linear correlation between label-free and QconCAT measurements in three samples ( $R^2 = 0.70$ ;  $R_s = 0.84$ ,  $P < 0.0001$ ) that were analyzed previously (Achour et al., 2014a), with measurements within 2.5-fold across the two methods (Fig. 1D). In the data of the present study, variability in cytochrome P450 and UGT enzyme abundances between

TABLE 2  
Rank orders, abundance levels, and primary subcellular localization of the 10 most abundant proteins in the analyzed HLM samples and those of drug-metabolizing cytochrome P450 enzymes

Overall Rank	Protein (Gene Name)	Overall Abundance		HLM01		HLM02		HLM03		HLM04	
		Mean $\pm$ S.D. <sup>a</sup> [pmol mg <sup>-1</sup> ]		Mean $\pm$ S.D. <sup>b</sup> [pmol mg <sup>-1</sup> ]	(Rank)	Mean $\pm$ S.D. <sup>b</sup> [pmol mg <sup>-1</sup> ]	(Rank)	Mean $\pm$ S.D. <sup>b</sup> [pmol mg <sup>-1</sup> ]	(Rank)	Mean $\pm$ S.D. <sup>b</sup> [pmol mg <sup>-1</sup> ]	(Rank)
<b>Top 10 HLM proteins</b>											
1	Liver carboxylesterase 1 <sup>c</sup>	403.14 $\pm$ 92.8		485.94 $\pm$ 24.31 (1)		396.81 $\pm$ 31.63 (1)		275.38 $\pm$ 13.45 (5)		454.42 $\pm$ 19.15 (1)	
2	Cytoplasmic actin 1 (ACTB) <sup>d</sup>	316.94 $\pm$ 74.63		325.51 $\pm$ 50.06 (8)		363.32 $\pm$ 21.94 (2)		370.02 $\pm$ 24.37 (2)		208.93 $\pm$ 23.54 (10)	
3	Protein disulfide isomerase (P4HB) <sup>e</sup>	304.25 $\pm$ 101.48		415.74 $\pm$ 12.23 (3)		324.86 $\pm$ 18.57 (3)		169.96 $\pm$ 4.02 (9)		306.44 $\pm$ 12.18 (2)	
4	78-kDa glucose-regulated protein (HSPA5) <sup>f</sup>	284.23 $\pm$ 62.67		352.90 $\pm$ 10.52 (6)		284.86 $\pm$ 24.83 (5)		201.29 $\pm$ 2.06 (8)		297.86 $\pm$ 10.86 (3)	
5	ATP synthase subunit $\beta$ (ATP5B) <sup>g</sup>	264.10 $\pm$ 96.66		140.23 $\pm$ 1.59 (24)		270.66 $\pm$ 25.62 (6)		376.41 $\pm$ 19.64 (1)		269.09 $\pm$ 2.31 (5)	
6	Protein disulfide isomerase A3 (PDIA3) <sup>h</sup>	262.73 $\pm$ 108.03		387.29 $\pm$ 12.61 (4)		252.14 $\pm$ 17.28 (7)		127.46 $\pm$ 2.23 (27)		286.05 $\pm$ 12.36 (4)	
7	Calreticulin (CALR) <sup>i</sup>	257.40 $\pm$ 86.90		372.06 $\pm$ 7.27 (5)		223.98 $\pm$ 36.44 (10)		166.32 $\pm$ 13.55 (11)		267.26 $\pm$ 4.77 (6)	
8	Haptoglobin (HP) <sup>j</sup>	253.47 $\pm$ 155.76		457.21 $\pm$ 34.92 (2)		292.00 $\pm$ 22.60 (4)		117.54 $\pm$ 10.34 (30)		147.11 $\pm$ 1.66 (21)	
9	Endoplasmic (HSP90B1) <sup>k</sup>	243.64 $\pm$ 78.95		335.09 $\pm$ 9.03 (7)		231.93 $\pm$ 17.82 (9)		144.52 $\pm$ 15.96 (14)		263.01 $\pm$ 6.13 (7)	
10	Cytochrome b5 (CYB5A) <sup>l</sup>	226.79 $\pm$ 18.36		251.61 $\pm$ 26.34 (11)		209.61 $\pm$ 15.40 (12)		217.01 $\pm$ 7.03 (6)		228.93 $\pm$ 36.13 (8)	
<b>Drug-metabolizing P450 enzymes<sup>c</sup></b>											
44	CYP3A4	80.87 $\pm$ 58.48		126.83 $\pm$ 4.43 (26)		134.71 $\pm$ 13.65 (26)		19.32 $\pm$ 1.63 (231)		42.64 $\pm$ 1.02 (122)	
53	CYP2E1	76.28 $\pm$ 14.78		73.50 $\pm$ 6.23 (57)		74.36 $\pm$ 8.85 (65)		60.84 $\pm$ 6.38 (78)		96.43 $\pm$ 13.80 (34)	
101	CYP2C9	50.37 $\pm$ 30.63		94.26 $\pm$ 13.22 (43)		29.89 $\pm$ 0.73 (192)		28.82 $\pm$ 0.40 (171)		48.49 $\pm$ 2.83 (106)	
108	CYP4F	48.31 $\pm$ 19.96		28.37 $\pm$ 2.56 (165)		68.91 $\pm$ 8.19 (70)		34.32 $\pm$ 1.79 (142)		61.63 $\pm$ 2.33 (80)	
109	CYP2A6	48.11 $\pm$ 43.44		108.60 $\pm$ 13.01 (36)		38.44 $\pm$ 3.53 (147)		5.11 $\pm$ 0.57 (597)		40.30 $\pm$ 1.37 (127)	
180	CYP3A5	31.07 $\pm$ 9.68		37.92 $\pm$ 4.13 (117)		24.22 $\pm$ 1.54 (231)		—		—	
186	CYP1A2	30.44 $\pm$ 7.19		24.25 $\pm$ 2.59 (184)		28.72 $\pm$ 2.81 (196)		—		38.33 $\pm$ 5.88 (134)	
201	CYP2C8	27.57 $\pm$ 25.42		64.37 $\pm$ 3.03 (66)		23.22 $\pm$ 1.72 (244)		6.92 $\pm$ 0.77 (516)		15.78 $\pm$ 1.25 (296)	
262	CYP2B6	20.98 $\pm$ 1.22		20.98 $\pm$ 1.22 (225)		—		—		—	
425	CYP2D6	12.45 $\pm$ 4.84		10.74 $\pm$ 1.07 (372)		—		17.91 $\pm$ 1.79 (245)		—	
560	CYP3A7	9.21 $\pm$ 0.62		9.21 $\pm$ 0.62 (413)		—		—		—	
815	CYP2C19	5.47 $\pm$ 0.69		5.96 $\pm$ 0.17 (542)		—		—		—	
1066	CYP3A43	1.06 $\pm$ 0.40		0.66 $\pm$ 0.11 (711)		1.20 $\pm$ 0.12 (814)		1.04 $\pm$ 0.11 (706)		4.98 $\pm$ 0.76 (604)	
51	NADPH cytochrome P450 reductase (POR) <sup>g</sup>	77.95 $\pm$ 19.18		85.88 $\pm$ 3.27 (53)		100.12 $\pm$ 5.52 (35)		55.97 $\pm$ 8.61 (87)		69.85 $\pm$ 3.27 (62)	

<sup>a</sup>S.D., representing combined biologic and technical variability.

<sup>b</sup>S.D., representing technical variability.


<sup>c</sup>Subcellular localization: endoplasmic reticulum.

<sup>d</sup>Subcellular localization: cytoplasm.

<sup>e</sup>Subcellular localization: mitochondria.

<sup>f</sup>Subcellular localization: secreted.


—Not quantifiable.



**Fig. 1.** Proteomic analysis of microsomal subproteome in the HLM samples showing the total number of identified and quantified proteins in the fraction the number of all drug-metabolizing enzymes (DME), drug-metabolizing cytochrome P450 enzymes (CYP450), and drug-metabolizing UGT enzymes (UGT) (B); Spearman correlation with linear regression of measurements of drug-metabolizing P450 and UGT enzymes using the label-free method described in this article and measurements of the same enzymes in three of the analyzed samples using the QconCAT targeted method (C); fold difference in abundance of enzymes of label-free measurements (method 1) in each sample relative to QconCAT measurements (method 2) expressed as a ratio ( $[x_{1,i} / x_{2,i}]$  for enzyme  $i$ ), with all pairs of measurements within approximately 2.5-fold (gray box) (D). Average fold error (AFE) is a measure of bias in the data, whereas absolute average fold error (AAFE) is a measure of scatter or spread of measurements; the closer these two measures are to 1, the lower the bias and scatter in measurement. Limited bias was seen in the two methods with a level of spread in the data (see Supplemental Table 3). (C) Abundances are expressed in units of  $\text{pmol mg}^{-1}$  HLM protein.

samples was estimated at up to 20-fold (total interindividual variability). Abundance values showed technical variability of less than 20% (CV) for all protein measurements. Therefore, the expected variability related to technical error (i.e., fold difference between the 5th and 95th centiles of measurements, calculated as  $(1 + 2 \text{ CV}) / (1 - 2 \text{ CV})$ , was 2-fold. This means technical variability constituted up to 10% of total variability (2-fold of a total of 20-fold). The variation resulting from the inherent reproducibility of MS-based experiments was therefore quite small compared with the biologic variability found in these samples.

**Protein Expression Profiles of DMEs.** Assessment of the protein expression levels of DMEs is summarized in Fig. 2. The assessed abundances were within reported values where literature was available (Fig. 2, A and B). The overlap between mid- and high-abundance drug-metabolizing P450 and UGT enzymes was approximately 80%, with the most abundant enzymes being CYP3A4, CYP2E1, CYP2C9, UGT2B4, and UGT2B7. The expression profiles of the quantified drug-metabolizing enzymes in the samples under study are shown in Fig. 2C, showing a distinct visual difference in the expression of enzymes in



**Fig. 2.** Patterns of expression of DMEs in liver samples: cytochrome P450 enzyme abundances compared with literature values (A), UGT abundances compared with literature values (B), patterns of expression of quantified DMEs in the HLM samples (C), and heat map of the expressed P450 and UGT enzymes with samples clustered using rank-order clustering (D). (A and B) Gray highlights indicate literature-derived ranges, bars indicate literature means and scatter points indicate experimentally derived values in this study. (C) BLQ is assigned for values below the limit of quantification. (D) The abundance values are normal log modified. Abundances are expressed in units of  $\text{pmol mg}^{-1}$  HLM protein

sample HLM03, which is confirmed by the heat map and rank-order cluster analysis shown in Fig. 2D.

**Components of HLM Fractions.** In the liver, hepatocytes are the primary site of drug metabolism. Along with hepatocytes, liver tissue contains other nonparenchymal cell types, including Kupffer, stellate, and biliary endothelial cells. HLMs are used as an *in vitro* model of drug metabolism, in early studies of drug development, but to date, their composition has not been systematically investigated.

A specific cell-surface marker for hepatocytes, asialoglycoprotein receptor 1 (Peters et al., 2016), was abundant in the microsomal fraction, whereas specific markers for other types of cells were not detected in any of the samples analyzed. Within hepatocytes, the main site of metabolism is the endoplasmic reticulum; however, other subcellular compartments, such as the cytosol and mitochondria, also contain DMEs. Figure 3A shows identified and quantified specific membrane marker proteins that reside in the membranes of different organelles within

hepatocytes (Vildhede et al., 2015). The most abundant markers were those of the endoplasmic reticulum membrane (calnexin), mitochondrial membrane (cytochrome *c* oxidase subunit 4), and plasma membrane (CD81, ATP1A1), with little difference in their abundances between analyzed samples. These specific markers suggest the presence of membranes from these compartments in the microsomal fraction and their contribution to drug metabolism in HLM preparations, although the extent of such contribution has yet to be systematically investigated.

The 10 most abundant proteins in HLM samples were localized mainly in the endoplasmic reticulum (Table 2); however, when the list is expanded to include all identified proteins (1276), the distribution of the HLM proteins was shown to be balanced between the endoplasmic reticulum (429 proteins), plasma membrane (406 proteins), cytosol/cytoplasm (411 proteins) and mitochondria (243 proteins), with overlap in a number of proteins between different compartments (Fig. 3B; Supplemental Fig. 5A). The localization of DMEs in different cellular

compartments and the corresponding overlap are also shown in Fig. 3C; Supplemental Fig. 5B, with most enzymes localized within the endoplasmic reticulum (50 enzymes).


Thus, although HLMs exhibit no detectable contamination from other hepatic cell types, these findings suggest that HLMs are far from pure in terms of subcellular composition, with many subcellular compartments other than endoplasmic reticulum being represented.

**Use of Total HLM Protein Mass for Enzyme Abundance Normalization.** Although drug-metabolizing cytochrome P450 and UGT enzymes are present mainly in the endoplasmic reticulum, normalization of abundance values has historically been done using total HLM protein mass, routinely measured using a colorimetric assay. HLM samples represent a mixture of proteins from different compartments, however, as shown already herein; therefore, the effect of the most highly expressed proteins in this system, which are not directly related to drug metabolism, was investigated in this study. The top part of Table 2 shows the 10 most abundant proteins in the microsomal samples, and for comparison, the bottom part shows the ranks and abundances of drug-metabolizing P450 enzymes. Figure 4A shows that although 600 proteins in the HLM fractions make up the bulk of sample mass (>99%), these top 10 proteins constitute approximately 15%–20% of protein mass in this fraction.


To assess the effect of expression variability in these 10 abundant proteins on endpoint measurement of drug-metabolizing cytochrome P450 enzymes, in terms of their abundance and correlation of expression, two simulations were performed, based on data from

literature studies, collated using meta-analysis, and our experimental data. The first simulation was intended to describe the effect of variation in the set of 10 abundant proteins on CYP3A4 abundance (Fig. 4B), and the second was intended to investigate the effects of variability in these proteins on correlation between CYP3A4 and CYP2C8 (reported in the literature to be strongly correlated,  $R_s = 0.68$ ,  $P < 0.0001$  (Achour et al., 2014b)). This latter simulation was intended to probe how much of the strong correlation could be attributed simply to the units of measurement.

Ten simulations of 2000 livers, each with variable CYP3A4 amounts (in picomoles expressed in 1 mg of tissue) showed that there is an overall significant decreasing trend in CYP3A4 abundance in units of picomoles per mg of HLM protein ( $R_s = -0.25$  to  $-0.20$ ,  $P < 0.0001$ ,  $n = 2000$ ), assuming independent regulation of expression. When the amount of CYP3A4 in simulated livers was kept constant in tissue at the median, the apparent abundance of CYP3A4 changed 1.4- to 1.7-fold as a function of overall random variability in the most abundant HLM proteins (Fig. 4B). When CYP2C8 and CYP3A4 were simulated independently (with variable amounts of these two enzymes in tissue), the level of correlation increased from  $R_s = 0.0$  (with no statistical significance) for random abundance values (decoy simulation) to correlation coefficients of approximately  $+0.1$  to  $+0.2$  ( $P < 0.0001$ ,  $n = 2000$ ) in 10 repeated simulations as a function of variability in the 10 most abundant proteins. These preliminary simulations suggest that the variation in the levels of proteins unrelated to drug metabolism can significantly influence the apparent levels of target enzymes if correction



**Fig. 3.** The abundance of specific membrane markers of hepatocytes (asialoglycoprotein receptor 1, ASGR1), endoplasmic reticulum (calnexin), plasma membrane (ATP1A1, CD81), mitochondria (COX4), and peroxisomes (PEX14) (A), subcellular localization of all identified proteins (B), and drug-metabolizing enzymes (C) in analyzed samples, providing an indication of the presence of membrane fractions from these organelles in HLMs. (A) Abundances are expressed in units of pmol mg<sup>-1</sup> HLM protein. (B and C) Percentages represent the proportions of proteins identified in each subcellular location to the total number of identified proteins, the sum of which adds up to more than 100% as a result of overlap in the localization of protein expression as shown in the Supplemental Material.



**Fig. 4.** Contribution of the 10 most abundant proteins to total HLM protein mass from four human livers (A) and simulated effect of variability of the top 10 proteins in HLM samples on CYP3A4 abundance in 2000 human livers (B). When the amount of CYP3A4 within tissue in simulated livers is kept constant, the abundance of CYP3A4 changes on average 1.4- to 1.7-fold, representing the effect of overall random variability in the most abundant proteins. Simulations were based on data obtained from this experimental study and a meta-analysis of available literature. (B) Abundances are expressed in units of  $\text{pmol mg}^{-1}$  HLM protein.

factors are not applied, such as milligrams of protein per gram of liver (MPPGL), to relate protein abundance levels to tissue mass instead of protein mass.

### Discussion

Qualitative and quantitative protein characterization can afford substantial insight into the biochemical state of cells (Collins et al., 2016), and proteomics is therefore becoming increasingly important in clinical and biomedical research. Scientists and clinicians are required to make important decisions as to whether to use a targeted approach to robustly analyze a limited set of proteins or to apply a nontargeted discovery-like method, which is more comprehensive but generally produces data of lower quality (Auffray et al., 2016; Collins et al., 2016). The present study involved the application of both approaches to HLM samples from the same patients to generate quantitative data for a set of DMEs, demonstrating the wide scope of analysis offered by the global (label-free) approach. It was particularly gratifying that the results showed good agreement with targeted quantification using QconCAT as a standard (Achour et al., 2015). Our results show that it is possible to obtain robust global proteomics measurements when quality control steps are taken to ensure successful implementation of quantitative analysis. In these experiments, there was rigorous quality control of sample preparation, standards, LC-IMS-MS/MS measurement, and data analysis. A similar assessment of label-free quantification of a set of yeast glycolytic enzymes also demonstrated agreement with quantification using QconCAT standards (Carroll et al., 2011), further supporting previous reports of consistency in measurements carried out within the same laboratory setting (Qiu et al., 2013; Prasad and Unadkat, 2014).

The global proteomic experiment was designed to be both robust and relatively quick. The time of the experiment was intended to be less than 1 hour to demonstrate the possibility of using this technique in screening processes. For this purpose, liquid chromatography, ion mobility and mass spectrometry were used to provide three layers of separation including the physical size of analyzed peptides (Supplementary Fig. 6) to analyze as many proteins as possible with high reliability (Distler et al., 2014). With this snapshot type of analysis, a set of a few hundred proteins (706–816) were successfully quantified, of which a subset of

63–76 drug and xenobiotic-metabolizing enzymes were characterized. The abundances of measured cytochrome P450 (12) and UGT (9) enzymes were within previously published literature ranges (Achour et al., 2014b, c). The phenotypic fingerprint generated using the expression profiles and the heat map of DMEs revealed a range of abundance levels exhibiting differences between the four individual samples, with rank-order cluster analysis showing sample HLM03 to have the most distinct expression profile.

Expression fingerprint of sample HLM03 showed overall lower abundances of a set of ADME proteins, exemplified by cytochrome P450 enzymes, including CYP1A2, CYP2A6, CYP2C9/19, and CYP3A4/5. Differences in the characteristics of the corresponding donor included exposure to medications, including an opioid analgesic (morphine) and a nonsteroidal anti-inflammatory agent (ibuprofen), as well as certain genetic differences, including polymorphic CYP2C9 (\*1/\*2), CYP2C19 (\*1/\*2), and CYP3A5 (\*3/\*3). Inflammatory conditions and polymorphism were previously reported to reduce the catalytic activity of CYP1A2, CYP2C9/19, and CYP3A4/5 (Zanger and Schwab, 2013; Zanger et al., 2014). Notably, a severe reduction in the expression levels of CYP3A5\*3/\*3 compared with the wild-type and CYP3A5\*1/\*3 variant is well documented in the literature (Lin et al., 2002; Achour et al., 2014a). In addition, murine hepatic expression of P450 enzymes after exposure to a derivative of morphine showed significantly lower abundances of CYP2C and CYP2E enzymes determined by using immunoblotting (Sheweita, 2003); however, because of the small sample size in the present study, the effects of these differences may require further investigation to confirm and elucidate them.

HLMs are routinely used in the metabolic characterization of new and existing compounds, with the idea that most of the metabolic activity in these systems is attributed to enzymes localized in the endoplasmic reticulum, which is believed to be preferentially enriched using differential centrifugation (Zhang et al., 2015); however, there is little evidence in the literature that defines the biomolecular composition of these fractions with suggestions that centrifugation can lead to either enrichment or loss of different membrane components (Harwood et al., 2014). For the purpose of addressing this gap, annotation related to subcellular localization was performed for all identified proteins in the analyzed HLM samples (1276 proteins). This revealed information



about the composition of this *in vitro* system, with the main components being the endoplasmic reticulum (34% of all proteins), the plasma membrane (32%), and the cytosol/cytoplasm (32%). Mitochondrial proteins also constituted a large proportion of proteins identified in HLM samples (19%). This finding is supported by the identification and quantification of specific membrane markers for the endoplasmic reticulum, mitochondria, and plasma membrane in this fraction, indicating that HLM samples represent a crude, heterogeneous mixture of proteins from different cell compartments (i.e., a crude total membrane fraction), including, but not limited to, the endoplasmic reticulum. Technical differences in the microsomal preparation method can theoretically lead to differences in the composition of the final microsomal fraction; however, the fractionation methods used by the suppliers of these samples were quite similar, and the abundances of marker proteins from different cell compartments were not significantly different. Importantly, the presence of proteins from the nucleus (11%) and Golgi body (12%) shows that the initial centrifugation step may require further optimization to achieve better enrichment of endoplasmic proteins. A useful approach to eliminate the effect of fractionation on measuring protein expression profiles may be to examine the expression levels in liver tissue homogenates instead.

A similar trend was seen with annotated drug and xenobiotic-metabolizing enzymes, with most enzymes coming from the endoplasmic reticulum (nearly 60%), the cytosol, and the plasma/exosomal membrane; however, the contribution of these non-endoplasmic reticulum enzymes to drug metabolism is only hypothesized at this stage. This observation of heterogeneity is in line with the findings of a recent global proteomic analysis that showed that the distribution of DMEs in fractions of liver tissue homogenate is complex (Wiśniewski et al., 2016b). Both the current work and that of Wiśniewski et al. point to caution in applying scaling factors when enzyme abundances are measured in membrane fractions.

Implications of this level of heterogeneity in HLMs are relevant to both the way abundance levels of ADME proteins are reported and the assessment of their correlations of expression. Abundance levels of enzymes and transporters have traditionally been measured in units of pmol/mg of total microsomal protein mass. We highlight two problems with this tradition. First, the total protein mass of microsomal samples represents proteins from different compartments of the cell, and the relative contribution of each compartment can, presumably, vary. In addition, the apparent expression of enzyme/transporter abundances can vary based on the total amount of protein in this system, even in cases where the level of the target enzyme/transporter is constant in tissue. In this study, the 10 most abundant proteins in HLM samples constituted 15%–20% of protein mass in these samples, and their expression can vary, leading to apparent variation in abundance of CYP3A4 by up to 1.7-fold ( $P < 0.0001$ ). Further, enzymes enriched in this system can achieve a level of background correlation based on the variability of unrelated but highly expressed proteins, a hypothesis proposed in our earlier reports (Achour et al., 2014b,c). This effect was simulated by randomly varying the amount of CYP2C8 and CYP3A4 in tissue and then normalizing by total protein mass with variations in the abundance of these 10 unrelated proteins. This simulation revealed a level of positive background correlation (Spearman correlation coefficient,  $R_s = +0.1$ – $+0.2$ ) with statistical significance ( $P < 0.0001$ ) for all assessed enzymes, further supporting the use of tissue mass, instead of total HLM protein mass, as the normalization factor, as previously advocated by Milne et al. (2011). The units of protein abundance would then be pmol mg<sup>-1</sup> tissue. Although strong correlations between enzymes with common genetic regulatory mechanisms are highly expected (Wortham et al., 2007; Jover et al., 2009), the reported level of background correlation encourages exercising caution when interpreting

and using weak to moderate expression relationships reported in the literature when abundance values are expressed in the traditional units, even if the correlation exhibits statistical significance.

In conclusion, this report constitutes a proof-of-principle study that demonstrates the utility of snapshot global profiling of enzymes in biologic systems as a screening method and raises cautionary arguments about using abundance levels of ADME proteins reported in the literature and their correlations of expression. The report also provides preliminary qualitative and quantitative details about the protein composition of HLM samples. Limitations of the current work are mainly the low sample size (four HLM samples), which renders comprehensive elucidation of interindividual variability in a population using the data in this report highly unlikely.

#### Acknowledgments

The authors thank Perdita Barran (University of Manchester) for facilitating and supporting this work; Douglas Kell and Dr. David Ellis (University of Manchester) for allowing laboratory access; Waters Corporation (Wilmslow, Manchester, UK) for providing access to LC-IMS-MS/MS instrumentation and data analysis software; the BioMS Core Research Facility, University of Manchester, for access to the MALDI-TOF MS instrument used in this study; Pfizer (Groton, CT) for providing the samples and related donor information; Dr. Khaled Rabie (Manchester Metropolitan University) for assistance with simulation software; and Jessica Waite and Eleanor Savill (Certara) for assistance with preparing the manuscript.

#### Authorship Contributions

*Participated in research design:* Achour, Rostami-Hodjegan, Barber.

*Conducted experiments:* Achour, Al Feteisi, Lanucara.

*Performed data analysis:* Achour, Lanucara.

*Wrote or contributed to the writing of the manuscript:* Achour, Rostami-Hodjegan, Barber.

#### References

- Achour B, Al-Majdoub ZM, Al Feteisi H, Elmorsi Y, Rostami-Hodjegan A, and Barber J (2015) Ten years of QconCATs: application of multiplexed quantification to small medically relevant proteomes. *Int J Mass Spectrom* **391**:93–104.
- Achour B and Barber J (2013) The activities of *Achromobacter* lysyl endopeptidase and *Lysobacter* lysyl endopeptidase as digestive enzymes for quantitative proteomics. *Rapid Commun Mass Spectrom* **27**:1669–1672.
- Achour B, Barber J, and Rostami-Hodjegan A (2014b) Expression of hepatic drug-metabolizing cytochrome p450 enzymes and their intercorrelations: a meta-analysis. *Drug Metab Dispos* **42**:1349–1356.
- Achour B, Rostami-Hodjegan A, and Barber J (2014c) Protein expression of various hepatic uridine 5'-diphosphate glucuronosyltransferase (UGT) enzymes and their inter-correlations: a meta-analysis. *Biopharm Drug Dispos* **35**:353–361.
- Achour B, Russell MR, Barber J, and Rostami-Hodjegan A (2014a) Simultaneous quantification of the abundance of several cytochrome P450 and uridine 5'-diphospho-glucuronosyltransferase enzymes in human liver microsomes using multiplexed targeted proteomics. *Drug Metab Dispos* **42**:500–510.
- Al Feteisi H, Achour B, Barber J, and Rostami-Hodjegan A (2015) Choice of LC-MS methods for the absolute quantification of drug-metabolizing enzymes and transporters in human tissue: a comparative cost analysis. *AAPS J* **17**:438–446.
- Al-Majdoub ZM, Carroll KM, Gaskell SJ, and Barber J (2014) Quantification of the proteins of the bacterial ribosome using QconCAT technology. *J Proteome Res* **13**:1211–1222.
- Auffray C, Caulfield T, Griffin JL, Khoury MJ, Lupski JR, and Schwab M (2016) From genomic medicine to precision medicine: highlights of 2015. *Genome Med* **8**:12.
- Badée J, Achour B, Rostami-Hodjegan A, and Galetin A (2015) Meta-analysis of expression of hepatic organic anion-transporting polypeptide (OATP) transporters in cellular systems relative to human liver tissue. *Drug Metab Dispos* **43**:424–432.
- Balogh LM, Kimoto E, Chupka J, Zhang H, and Lai Y (2013) Membrane protein quantification by peptide-based mass spectrometry approaches: studies on the organic anion-transporting polypeptide family. *J Proteomics Bioinform* **6**:229–236.
- Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. *Anal Biochem* **72**:248–254.
- Burnum-Johnson KE, Nie S, Casey CP, Monroe ME, Orton DJ, Ibrahim YM, Gritsenko MA, Clauss TRW, Shukla AK, Moore RJ, et al. (2016) Simultaneous proteomic discovery and targeted monitoring using liquid chromatography, ion mobility spectrometry, and mass spectrometry. *Mol Cell Proteomics* **15**:3694–3705.
- Carroll KM, Simpson DM, Evers CE, Knight CG, Brownridge P, Dunn WB, Winder CL, Lanthaler K, Pir P, Malys N, et al. (2011) Absolute quantification of the glycolytic pathway in yeast: deployment of a complete QconCAT approach. *Mol Cell Proteomics* **10**:007633.
- Chiva C, Ortega M, and Sabidó E (2014) Influence of the digestion technique, protease, and missed cleavage peptides in protein quantitation. *J Proteome Res* **13**:3979–3986.

- Collins BC, Hunter CL, Liu Y, Schilling B, Rosenberger GR, Bader SL, Chan DW, Gibson BW, Gingras AC, Held JM, et al. (2016) Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. *bioRxiv*:074567.
- Distler U, Kuharev J, Navarro P, Levin Y, Schild H, and Tenzer S (2014) Drift time-specific collision energies enable deep-coverage data-independent acquisition proteomics. *Nat Methods* **11**:167–170.
- Ehmann F, Caneva L, Prasad K, Paulmichl M, Maliepaard M, Llerena A, Ingelman-Sundberg M, and Papaluca-Amati M (2015) Pharmacogenomic information in drug labels: European Medicines Agency perspective. *Pharmacogenomics J* **15**:201–210.
- Fallon JK, Neubert H, Hyland R, Goosen TC, and Smith PC (2013) Targeted quantitative proteomics for the analysis of 14 UGT1As and -2Bs in human liver using NanoUPLC-MS/MS with selected reaction monitoring. *J Proteome Res* **12**:4402–4413.
- Fallon JK, Smith PC, Xia CQ, and Kim MS (2016) Quantification of four efflux drug transporters in liver and kidney across species using targeted quantitative proteomics by isotope dilution nanoLC-MS/MS. *Pharm Res* **33**:2280–2288.
- Gröer C, Brück S, Lai Y, Paulick A, Busemann A, Heidecke CD, Siegmund W, and Oswald S (2013) LC-MS/MS-based quantification of clinically relevant intestinal uptake and efflux transporter proteins. *J Pharm Biomed Anal* **85**:253–261.
- Harwood MD, Achour B, Russell MR, Carlson GL, Warhurst G, and Rostami-Hodjegan A (2015) Application of an LC-MS/MS method for the simultaneous quantification of human intestinal transporter proteins absolute abundance using a QconCAT technique. *J Pharm Biomed Anal* **110**:297–33.
- Harwood MD, Achour B, Neuhoff S, Russell MR, Carlson G, Warhurst G, and Rostami-Hodjegan A (2016) In vitro-in vivo extrapolation scaling factors for intestinal P-glycoprotein and breast cancer resistance protein. Part I. A cross-laboratory comparison of transporter-protein abundances and relative expression factors in human intestine and Caco-2 cells. *Drug Metab Dispos* **44**:297–307.
- Harwood MD, Russell MR, Neuhoff S, Warhurst G, and Rostami-Hodjegan A (2014) Lost in centrifugation: accounting for transporter protein losses in quantitative targeted absolute proteomics. *Drug Metab Dispos* **42**:1766–1772.
- Huang SM, Abernethy DR, Wang Y, Zhao P, and Zineh I (2013) The utility of modeling and simulation in drug development and regulatory review. *J Pharm Sci* **102**:2912–2923.
- Jamei M (2016) Recent advances in development and application of physiologically-based pharmacokinetic (PBPK) models: a transition from academic curiosity to regulatory acceptance. *Curr Pharmacol Rep* **2**:161–169.
- Jover R, Moya M, and Gómez-Lechón MJ (2009) Transcriptional regulation of cytochrome p450 genes by the nuclear receptor hepatocyte nuclear factor 4-alpha. *Curr Drug Metab* **10**:508–519.
- Kim N, Park H, He N, Lee HY, and Yoon S (2012) QCanvas: an advanced tool for data clustering and visualization of genomics data. *Genomics Inform* **10**:263–265.
- Knights KM, Spencer SM, Fallon JK, Chau N, Smith PC, and Miners JO (2016) Scaling factors for the in vitro-in vivo extrapolation (IV-IVE) of renal drug and xenobiotic glucuronidation clearance. *Br J Clin Pharmacol* **81**:1153–1164.
- Lin YS, Dowling AL, Quigley SD, Farin FM, Zhang J, Lamba J, Schuetz EG, and Thummel KE (2002) Co-regulation of CYP3A4 and CYP3A5 and contribution to hepatic and intestinal midazolam metabolism. *Mol Pharmacol* **62**:162–172.
- Masys DR, Jarvik GP, Abernethy NF, Anderson NR, Papanicolaou GJ, Paltoo DN, Hoffman MA, Kohane IS, and Levy HP (2012) Technical desiderata for the integration of genomic data into Electronic Health Records. *J Biomed Inform* **45**:419–422.
- McGrath S and Ghersi D (2016) Building towards precision medicine: empowering medical professionals for the next revolution. *BMC Med Genomics* **9**:23.
- Milne AM, Burchell B, and Coughtrie MWH (2011) A novel method for the immunoquantification of UDP-glucuronosyltransferases in human tissue. *Drug Metab Dispos* **39**:2258–2263.
- Ohtsuki S, Schaefer O, Kawakami H, Inoue T, Liehner S, Saito A, Ishiguro N, Kishimoto W, Ludwig-Schwelling E, Ebner T, et al. (2012) Simultaneous absolute protein quantification of transporters, cytochromes P450, and UDP-glucuronosyltransferases as a novel approach for the characterization of individual human liver: comparison with mRNA levels and activities. *Drug Metab Dispos* **40**:83–92.
- Peters DT, Henderson CA, Warren CR, Friesen M, Xia F, Becker CE, Musunuru K, and Cowan CA (2016) Asialoglycoprotein receptor 1 is a specific cell-surface marker for isolating hepatocytes derived from human pluripotent stem cells. *Development* **143**:1475–1481.
- Prasad B, Evers R, Gupta A, Hop CE, Salphati L, Shukla S, Ambudkar SV, and Unadkat JD (2014) Interindividual variability in hepatic organic anion-transporting polypeptides and P-glycoprotein (ABC B1) protein expression: quantification by liquid chromatography tandem mass spectrometry and influence of genotype, age, and sex. *Drug Metab Dispos* **42**:78–88.
- Prasad B and Unadkat JD (2014) Comparison of heavy labeled (SIL) peptide versus SILAC protein internal standards for LC-MS/MS quantification of hepatic drug transporters. *Int J Proteomics* **2014**:451510.
- Qiu X, Bi YA, Balogh LM, and Lai Y (2013) Absolute measurement of species differences in sodium taurocholate cotransporting polypeptide (NTCP/Ntcp) and its modulation in cultured hepatocytes. *J Pharm Sci* **102**:3252–3263.
- Rostami-Hodjegan A (2012) Physiologically based pharmacokinetics joined with in vitro-in vivo extrapolation of ADME: a marriage under the arch of systems pharmacology. *Clin Pharmacol Ther* **92**:50–61.
- Russell MR, Achour B, Mckenzie EA, Lopez R, Harwood MD, Rostami-Hodjegan A, and Barber J (2013) Alternative fusion protein strategies to express recalcitrant QconCAT proteins for quantitative proteomics of human drug metabolizing enzymes and transporters. *J Proteome Res* **12**:5934–5942.
- Schadt EE and Björkegren JL (2012) NEW: network-enabled wisdom in biology, medicine, and health care. *Sci Transl Med* **4**:115rv1.
- Schaefer O, Ohtsuki S, Kawakami H, Inoue T, Liehner S, Saito A, Sakamoto A, Ishiguro N, Matsumaru T, Terasaki T, et al. (2012) Absolute quantification and differential expression of drug transporters, cytochrome P450 enzymes, and UDP-glucuronosyltransferases in cultured primary human hepatocytes. *Drug Metab Dispos* **40**:93–103.
- Sheweita SA (2003) Narcotic drugs change the expression of cytochrome P450 2E1 and 2C6 and other activities of carcinogen-metabolizing enzymes in the liver of male mice. *Toxicology* **191**:133–142.
- Silva JC, Gorenstein MV, Li GZ, Vissers JP, and Geromanos SJ (2006) Absolute quantification of proteins by LCMS<sup>2</sup>: a virtue of parallel MS acquisition. *Mol Cell Proteomics* **5**:144–156.
- Turner RM, Park BK, and Pirmohamed M (2015) Parsing interindividual drug variability: an emerging role for systems pharmacology. *Wiley Interdiscip Rev Syst Biol Med* **7**:221–241.
- Vildhede A, Wiśniewski JR, Norén A, Karlgren M, and Artursson P (2015) Comparative proteomic analysis of human liver tissue and isolated hepatocytes with a focus on proteins determining drug exposure. *J Proteome Res* **14**:3305–3314.
- Weiß F, Schnabel A, Planatscher H, van den Berg BH, Serschnitzki B, Nuessler AK, Thasler WE, Weiss TS, Reuss M, Stoll D, et al. (2015) Indirect protein quantification of drug-transforming enzymes using peptide group-specific immunoaffinity enrichment and mass spectrometry. *Sci Rep* **5**:8759.
- Wiśniewski JR, Hein MY, Cox J, and Mann M (2014) A “proteomic ruler” for protein copy number and concentration estimation without spike-in standards. *Mol Cell Proteomics* **13**:3497–3506.
- Wiśniewski JR and Mann M (2012) Consecutive proteolytic digestion in an enzyme reactor increases depth of proteomic and phosphoproteomic analysis. *Anal Chem* **84**:2631–2637.
- Wiśniewski JR, Vildhede A, Norén A, and Artursson P (2016a) In-depth quantitative analysis and comparison of the human hepatocyte and hepatoma cell line HepG2 proteomes. *J Proteomics* **136**:234–247.
- Wiśniewski JR, Wegler C, and Artursson P (2016b) Subcellular fractionation of human liver reveals limits in global proteomic quantification from isolated fractions. *Anal Biochem* **509**:82–88.
- Wortham M, Czerwinski M, He L, Parkinson A, and Wan Y-JY (2007) Expression of constitutive androstane receptor, hepatic nuclear factor 4 alpha, and P450 oxidoreductase genes determines interindividual variability in basal expression and activity of a broad scope of xenobiotic metabolism genes in the human liver. *Drug Metab Dispos* **35**:1700–1710.
- Zanger UM and Schwab M (2013) Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. *Pharmacol Ther* **138**:103–141.
- Zanger UM, Klein K, Thomas M, Rieger JK, Tremmel R, Kandel BA, Klein M, and Magdy T (2014) Genetics, epigenetics, and regulation of drug-metabolizing cytochrome p450 enzymes. *Clin Pharmacol Ther* **95**:258–261.
- Zhang H, Gao N, Tian X, Liu T, Fang Y, Zhou J, Wen Q, Xu B, and Qi BGao J and Li H (2015) Content and activity of human liver microsomal protein and prediction of individual hepatic clearance in vivo. *Sci Rep* **5**:17671.

---

**Address correspondence to:** Dr. Jill Barber, Division of Pharmacy and Optometry, School of Health Sciences, University of Manchester, Stopford Building, Oxford Road, Manchester, M13 9PT, UK. E-mail: Jill.Barber@manchester.ac.uk

---